Dermira (NASDAQ: DERM) is one of 296 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare Dermira to similar businesses based on the strength of its earnings, institutional ownership, analyst recommendations, risk, profitability, dividends and valuation.

Institutional & Insider Ownership

97.7% of Dermira shares are held by institutional investors. Comparatively, 50.4% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 13.3% of Dermira shares are held by company insiders. Comparatively, 16.4% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and target prices for Dermira and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dermira 3 0 5 0 2.25
Dermira Competitors 767 3061 11246 227 2.71

Dermira currently has a consensus target price of $44.40, suggesting a potential upside of 65.86%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 35.69%. Given Dermira’s higher possible upside, equities research analysts clearly believe Dermira is more favorable than its rivals.

Volatility and Risk

Dermira has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500. Comparatively, Dermira’s rivals have a beta of 6.66, suggesting that their average stock price is 566% more volatile than the S&P 500.

Profitability

This table compares Dermira and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Dermira -408.50% -31.66% -22.59%
Dermira Competitors -5,458.35% -450.70% -43.40%

Earnings & Valuation

This table compares Dermira and its rivals revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Dermira $24.72 million -$102.21 million -10.10
Dermira Competitors $263.26 million $68.25 million -6.44

Dermira’s rivals have higher revenue and earnings than Dermira. Dermira is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Dermira rivals beat Dermira on 7 of the 12 factors compared.

Dermira Company Profile

Dermira, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor, or TNF inhibitor that is approved and marketed for the treatment of numerous inflammatory diseases spanning multiple medical specialties, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn’s disease, in multiple countries, including the United States. Glycopyrronium tosylate is a small molecule anticholinergic product for topical application for the treatment of primary axillary hyperhidrosis. Olumacostat glasaretil is a small molecule that targets sebum production following topical application for the treatment of acne.

Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.